Issue |
SHS Web Conf.
Volume 144, 2022
2022 International Conference on Science and Technology Ethics and Human Future (STEHF 2022)
|
|
---|---|---|
Article Number | 01006 | |
Number of page(s) | 5 | |
Section | Research on Bioethics and Medical Science and Technology Ethics | |
DOI | https://doi.org/10.1051/shsconf/202214401006 | |
Published online | 26 August 2022 |
Potential Drug Delivery Pathways for Treatment of Alzheimer’s Disease
College of Letters and Science, University of California Los Angeles, Los Angeles, California, United States, 90024
* Corresponding author. Email: sallywang@ucla.edu
Alzheimer’s Disease (AD) has been one of the most prevalent neurodegenerative disorders that majorly affect patients older than 65 years old. The treatment of the disease costs over 1% of the global GDP [1], yet not many new drugs have been developed which can effectively treat AD based on its pathological characteristics. The major challenge in treating brain disorders such as AD is the Blood-Brain Barrier (BBB) which refrains most of the drug molecules from entering the brain. Through reviewing multiple papers from PubMed Central®(PMC), which is an archive of biomedical and life sciences journal literature at the U.S. National Institutes of Health’s National Library of Medicine (NIH/NLM), three promising drug delivery pathways have been investigated regarding their capabilities and effectivenesses of transporting drug molecules into the brain, which are inorganic nanoparticles, multifunctional liposomes, and transdermal delivery system. In this paper, brief introductions regarding each delivery pathway were offered, and specific experiment that supported the delivery method was presented. The advantages, as well as drawbacks of each type of delivery pathway, were also discussed in this paper.
© The Authors, published by EDP Sciences, 2022
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.